Danger at the Drugstore
Too many pharmacists fail to protect consumers against
potentially hazardous interactions of prescription drugs
By SUSAN HEADDEN
with TRACY
LENZY, PAUL OSTYU, KAREN ROEBUCK,
LAURA LOCKE, BARBARA
BURGOWER HORDERN, STEVE
BEAVEN, AND
RUTH MULLEN
Source:
U.S. News Online 8/26/96
(? U.S.News & World Report, Inc. All rights reserved.)
A Philadelphia CVS store makes
the point with a gum machine filled with colorful prescription drugs:
"This is not," the sign says, "how it works." Far from just pill
dispensers, the message reminds customers, pharmacists deserve respect as
important partners with other healthcare providers in the field of disease
management. They are getting it, too. In 11 states, pharmacists have been
granted the limited right to prescribe certain medications?a privilege
traditionally reserved for doctors. More generally, pharmacists are
regarded as among the nation's most admired professionals. In several
recent Gallup polls, for instance, Americans ranked pharmacists above
doctors, teachers, even clergymen.
That's the perception. The
reality, according to an exclusive new study by U.S. News in
cooperation with Georgetown University School of Medicine, is that many of
the nation's pharmacists are falling down on the job. In particular, they
are failing to protect consumers against dangerous interactions of
prescription drugs, an exploding health-care problem that sends hundreds
of thousands of Americans to the hospital every year.
The U.S. News
investigation, which tested 245 pharmacies in seven cities, found that
well over half of all pharmacists failed to warn consumers when presented
with prescriptions for drugs that, when taken separately, are safe but
when taken together can be at best risky and at worst deadly. So dangerous
was one interaction that medical experts said the prescriptions should
never have been filled at all. Yet a disturbing one third of pharmacists
dispensed both medications with no comment beyond, "Thank you, have a nice
day." The results, says Dr. Marcus Reidenberg, a pharmacologist at New
York Hospital?Cornell Medical Center, "prove that systems to correct
prescription errors in this country are of very limited reliability." Says
Dr. Thorir Bjornsson of Jefferson Medical College in Philadelphia: "The
disappointing results of this study should serve as a wake-up call to the
entire industry."
The magazine's investigation
expands on a study earlier this year of pharmacists in Washington, D.C.,
by researchers at the Georgetown University Medical Center's Division of
Clinical Pharmacology. That study found that more than 30 percent of
Washington pharmacists did not challenge doctors who simultaneously
prescribed the potentially deadly mix of Seldane, the popular non-sedating
antihistamine, and erythromycin, a common antibiotic. Working with
Georgetown's Dr. Raymond Woosley, who conducted the study with colleagues
Dr. Nicholas Cavuto and Dr. Mark Sale, U.S. News asked seven
physician-pharmacologists to write prescriptions for three other drug
combinations with reactions of varying degrees of familiarity and
severity. A pharmacist was considered to have warned the patient if he
counseled him, offered to call the doctor or refused to fill the
prescriptions. The findings:
About one third of pharmacists
did not alert consumers to the potentially severe and widely publicized
interaction between Hismanal, a common antihistamine, and Nizoral, an
often-prescribed antifungal drug. Like Seldane and erythromycin, the
Hismanal-Nizoral mix can cause irregular heartbeat, cardiac arrest and
sudden death. Clearly contraindicated, the prescriptions prompted such
stunned druggist reactions as "What was your doctor thinking?"
and "Don't even try to fill this prescription anywhere else." But 32
percent of the pharmacists dispensed the potentially lethal combination
with no verbal warning, and half of those filled it with only a vague
written caution. Some pharmacists went so far as to counsel consumers to
take Hismanal on an empty stomach and Nizoral with food but were silent
on the fact that taking them together could kill the patient.
Only four out of 17
pharmacists warned of the acute interaction between oral contraceptives
and Rimactane, an antibiotic used to treat tuberculosis. Like some other
antibiotics, Rimactane diminishes the effect of birth-control drugs and
can render them ineffective. "Heck, yeah, an unintended pregnancy when
you're on birth control deserves a verbal warning," says Reidenberg,
echoing widespread medical opinion. But 77 percent of those surveyed
didn't issue verbal warnings; fewer than half included a written
suggestion to use a backup contraceptive.
Only three out of 61
pharmacists issued any verbal warnings about the interaction between
Vasotec and Dyazide, both drugs used to control high blood pressure.
Used together, these drugs can trigger a condition called hyperkalemia,
an abnormally high level of potassium that can cause dizziness, heart
failure and death. The risk of heart attack is low, and the condition
rare, but, says Dr. Bjornsson, "the public needs to know that,
especially if they are just starting out taking the two drugs." Of the
61 pharmacists asked to fill prescriptions for the two, only one
declined to do so.
Consumers' chances of being
alerted to potentially dangerous drug interactions varied widely among
the cities surveyed. In Denver, more than half the pharmacists tested
dispensed Hismanal?Nizoral without verbal warnings. In suburban New
York, 40 percent did. But Indianapolis pharmacists were a far more
cautious lot: All but three of 20 pharmacists surveyed refused to fill
the prescriptions, and the three who did fill them issued strong
warnings against taking the two drugs together.
Fewer than half the pharmacies
surveyed included written warnings with the drugs after filling the
prescriptions, and what warnings there were varied considerably in
usefulness and reliability. A minority offered detailed information
about interactions; more often, the warnings counseled patients simply
to "talk with your physician if you are taking other medications."
Thorough or not, written alerts are no substitute for verbal warnings:
"Even my wife throws them away," says Columbus, Ohio, pharmacist Martin
Ruehle.
Although independent drugstores
represented half the total pharmacies tested, they accounted for nearly
two thirds of the pharmacies that failed to warn consumers of the most
dangerous of the three drug interactions. And while pharmacies in low- and
lower-middle-income neighborhoods represented less than half the total
survey sample, they accounted for nearly two thirds of the pharmacies that
failed to warn consumers of the most dangerous interactions.
The magazine's findings come at
a time of unprecedented prescription drug use in the United States?and
growing concern about side effects. Filling more than 2 billion
prescriptions a year, pharmacists are widely regarded as the last line of
defense in catching doctors' prescribing errors and preventing drug
mishaps that, according to the U.S. General Accounting Office, cost an
estimated $20 billion a year. It's a responsibility they willingly
shoulder. Pharmacists are quick to point out that six years of rigorous
training in such specialized disciplines as toxicology, pharmacokinetics
(the study of how drugs move through the body) and pharmacology make them
far more expert in matters pharmaceutical than their colleagues with the
medical degrees.
At the same time, however,
increasing financial turmoil in the retail drug business has pharmacists
working under greater stress. According to the National Association of
Retail Druggists, 3,000 independent pharmacies have gone out of business
in the past two years?victims of competition from big drug-, grocery- and
department-store chains. Even more threatening are pressures from health
maintenance organizations, which now cover many pharmacy customers. HMOs
have slashed reimbursement rates to the point where pharmacies often get
reimbursed at rates well below what the drugs cost them. "Pharmacy is no
longer a pleasant profession," says William Sullivan, former owner of a
San Francisco-area pharmacy. "I wouldn't recommend it to anyone."
Dangerous Mix
Like the mixture of certain
drugs in dangerous combinations, the dual pressures of rising costs and
greater competition are a prescription for trouble. Many pharmacists
surveyed conceded that their failure to catch dangerous drug interactions
was impossible to justify ("Whoever filled this prescription shouldn't
even be a pharmacist," said a shaken Denver druggist on learning his
assistant dispensed Hismanal?Nizoral without warning). But most also
seized the opportunity to blast insurers for the financial pressures that
cause them to work 12 hours a day with hardly a break to build higher
volume and make up for lower prices. Meantime, pharmacists are supervising
greater numbers of lesser-trained technicians. "This place is a
sweatshop," says a pharmacist at a Denver area Kmart, still counting pills
while talking with a reporter. Too often, druggists say, time arguing with
insurers eats into the time pharmacists should be taking to counsel
customers about their prescriptions.
Doctors tend to sympathize with
the pharmacists' plight. But they argue?and many pharmacists agree? that
druggists are professionally obligated to catch and prevent prescription
errors even when they are not legally liable. And increasingly they are
legally liable. A 1990 federal law requires pharmacists to offer
counseling to all Medicaid patients, and more than 40 states have since
elected to expand that protection to all patients. Pharmacists who
advertise these services may be even more vulnerable. In an opinion apt to
affect the entire retail drug industry, a Michigan State Court of Appeals
ruled recently that pharmacists had assumed a legal duty to warn consumers
when they implemented and advertised a computer system that checked for
adverse drug interactions before filling a prescription. In the 1996 case,
Baker v. Arbor Drugs, it was claimed a Wyandotte, Mich., pharmacist
failed to warn a customer of the adverse effects of taking Parnate, an
antidepressant, and the decongestant Tavist-D in combination. The patient
suffered a stroke as a result of the interaction and later killed himself.
In light of the Michigan ruling,
the actions of a suburban Philadelphia pharmacy tested by U.S. News
take on particular significance. In every bag containing prescription
drugs sold to customers, the pharmacy included a flier stating, "Every
prescription filled for you is entered in our Patient Profile System so we
can check for drug interactions and allergies. . . . We will warn you of
any expected side effects." Despite these assurances, the pharmacy
dispensed the potentially lethal Hismanal-Nizoral combination without a
word of warning to a reporter.
That was not an exception
either. Indeed, many actions of pharmacists tested by U.S. News
ranged from the mystifying to the downright reckless. Asked why his
drugstore filled prescriptions for Hismanal?Nizoral, a Philadelphia
pharmacist replied that he was on vacation at the time and that the
prescriptions were filled by his assistant?a lawyer. In Denver, a
pharmacist explained that she was well aware of the dangerous
Hismanal?Nizoral interaction, but because it didn't pop up on her
computer, she didn't mention it. Another independent pharmacist in
Philadelphia said he didn't report the birth-control pill?Rimactane
interaction because Rimactane didn't render the contraceptive
completely ineffective, only partially ineffective. In
Columbus, a young pharmacist explained her failure to warn of the danger
of taking Hismanal and Nizoral in combination this way: "I'm new," she
said. "I've never dispensed a drug in my life."
In several cases, pharmacists
who touted personal service and pledged to counsel patients seemed to
violate their own policies. "We always have time to talk to customers,"
asserted an independent pharmacist in suburban Philadelphia. But he was at
a loss to explain why he didn't warn a reporter of the dangers of taking
Rimactane and a birth-control drug when he filled the prescriptions for
the two medications. In Denver, a Safeway pharmacist attached warnings to
bottles of Hismanal and Nizoral, then covered them by slapping "thank you"
stickers on top of them. One Houston Walgreen store filled the
Hismanal-Nizoral combination without comment; another in the same city
wouldn't let the drugs out the door. Similar inconsistencies occurred
among pharmacies operated by other big chains, including Safeway, Wal-Mart
and Kroger.
Computerized Database
Virtually all pharmacies today
use computer programs that display the levels of severity of a drug
interaction, from moderate to severe. But whether their databases are
outdated, inaccurate or simply unheeded is not clear. The Hismanal-Nizoral
combination shows up on databases as a Level 1 interaction, the most
serious. Under the entry for Hismanal (generically known as astemizole) in
the Physician's Desk Reference, an unmistakable boxed warning in boldface
type clearly states: "Concomitant administration of astemizole with
ketoconozole [Nizoral] is contraindicated." That means the two drugs
should never be taken together. Yet several pharmacists, without
consulting the prescribing physician, addressed the problem of filling the
two drugs in combination by directing the customer to start taking one
drug after finishing the other. A Columbus pharmacist, noting that a
doctor had neglected to include a specific dosage, added his own
instructions to "take as directed." In both cases, says Georgetown's
Woosley, the pharmacist exceeded his authority. In fact, Woosley and other
experts say, no pharmacist should have filled the Hismanal-Nizoral
prescriptions in the first place.
Pharmacists apparently applied a
different standard to the Vasotec-Dyazide combination tested by U.S.
News, since there are no prohibitions against the two drugs being
prescribed together. While most pharmacies included literature about the
individual drugs, only two mentioned the specific interaction between
them. Most pharmacists who responded to the survey results, including
those who warned customers against taking the other drugs in combination,
said they wouldn't warn about the Vasotec-Dyazide interaction since
doctors often experiment with different combinations of heart medications
and monitor patients carefully. Further, Vasotec-Dyazide is classified as
a Level 2 interaction, not as risky as, say, Hismanal-Nizoral. The
pharmacists' actions, says Woosley, seem to suggest that many are now too
busy to discuss anything but Level 1 interactions. That may be
understandable in today's cost-conscious climate, he says, but it still is
troubling. Dr. David Kessler, the commissioner of the federal Food and
Drug Administration, views the results of the U.S. News
survey in a harsher light: "It is simply untenable in 1996 to walk into a
pharmacy and receive a bottle of pills and no other information. It is not
good patient care."
Misplaced Trust
As important as they are to
customers seeking to cure or manage illness, pharmacists are just one link
in a chain of safeguards intended to prevent prescription errors. The most
crucial link is the doctor. Thus, many pharmacists told U.S. News
that when the same doctor prescribes two interacting drugs, they are less
likely to question his judgment. "If the prescriptions came from two
different doctors, that would warrant a call," says pharmacist Gordon Tom
of San Francisco. "But if it's the same doctor, we assume he's aware of
the interaction." Recent studies show that such trust is often misplaced.
The Seldane- erythromycin interaction is a case in point: Despite widely
disseminated warnings by the drugs' manufacturers and the federal Food and
Drug Administration, 3 to 10 percent of doctors last April still were
prescribing the two drugs together.
Such mistakes, pharmacologists
say, point to serious gaps in physicians' education in pharmacology?as
well as to limitations in basic, clinical research on the actions of
prescription drugs. Not surprisingly, the pharmaceutical industry focuses
its clinical studies on finding the positive impact of drugs. Far fewer
resources are devoted to the study of adverse drug effects and drug
interactions. Academic medical centers have proposed a federally
authorized network of researchers who would study the causes of drug
interactions and educate doctors, nurses and pharmacists on prescriptive
drugs.
Given the potential severity of
the drug-interaction problem, reformers like the FDA's Kessler have been
frustrated by the efforts of pharmacies and pharmaceutical manufacturers
to block other federal solutions. It took more than 15 years for the FDA
to secure passage of a law this summer that will require pharmacists to
distribute uniform and easy-to-understand information with every new
prescription or refill by the year 2006. Manufacturers, fearing that too
many warnings will only confuse customers, say voluntary efforts will
suffice.
In any event, many pharmacists
say their business cannot continue on its current course if it is to meet
the two competing goals of educating patients and making a profit from
prescription drugs in an atmosphere of managed care. "We find ourselves
significantly challenged," says Dr. John Gans, executive vice president of
the American Pharmaceutical Association. "We are looking at a
re-engineering of the whole profession."
As is already the practice in
doctors' offices, pharmacists want to concentrate on their clinical tasks
and delegate financial matters to clerks. But it may be a while before
that transformation occurs. Managed-care companies would have to change
their pricing structures to give pharmacists more incentive to judge and
report the clinical significance of the interactions and side effects that
accompany nearly every prescribed drug. They also would have to boost
compensation to allow for more clerks to ring up sales and handle
questions of reimbursement. Since that is unlikely to happen anytime soon,
says Gans, patients have little choice but to look out for themselves.
Simply put, he says, "You have to manage your own care."
Related Links
Pharmaceutical Information
Network.
Hunt through this comprehensive directory of links, databases and
resources.
U.S. Food and Drug
Administration.
Get news on the latest government approved drugs and investigations.
Merck.
Offers product information, descriptions of medical disorders, plus a
dictionary of drug names.
Institute for
Safe Medication Practices.
This group's newsletter warns against deadly drug interactions.
HealthTouch.
Search for a drug's indications and side effects.
|